Chlorinated tetralin compounds and pharmaceutical compositions

1. A method of treating a desmoid tumor in a patient in need thereof comprising administering a pharmaceutical composition comprising a compound of Formula IA

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 200 μg.

3. The method of claim 1 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 150 μg.

4. The method of claim 1 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 100 μg.

5. The method of claim 1 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 50 μg.

6. The method of claim 1 , wherein the pharmaceutical composition further comprises nirogacestat or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 200 μg.

8. The method of claim 7 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

9. The method of claim 6 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 150 μg.

10. The method of claim 9 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

11. The method of claim 6 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 100 μg.

12. The method of claim 11 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.

13. The method of claim 6 , wherein the compound of Formula IA or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 50 μg.

14. The method of claim 13 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.